Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies.
暂无分享,去创建一个
J Jack Lee | Razelle Kurzrock | Chaan Ng | J. Lee | C. Ng | R. Kurzrock | A. Naing | D. Hong | J. Wheler | R. Jain | Aung Naing | David Hong | Jennifer Wheler | Rajul K Jain | Jing Gong | Jing Gong | J. Lee
[1] D. Lane. Reporting results from chemotherapy trials. , 1985, JAMA.
[2] W. Cleveland,et al. Locally Weighted Regression: An Approach to Regression Analysis by Local Fitting , 1988 .
[3] Lesley Seymour,et al. An Overview of the Optimal Planning, Design, and Conduct of Phase I Studies of New Therapeutics , 2010, Clinical Cancer Research.
[4] J. Humm,et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study , 2010, The Lancet.
[5] M. Lipsett. On the nature and ethics of phase I clinical trials of cancer chemotherapies. , 1982, JAMA.
[6] M. Buyse,et al. Phase I Cancer Clinical Trials: A Practical Guide , 2006 .
[7] S. Curley,et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. , 2009, JAMA.
[8] M Paesmans,et al. Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working Party. , 1997, European journal of cancer.
[9] M. Christian,et al. Phase I clinical trial design in cancer drug development. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] J R Anderson,et al. Analysis of survival by tumor response. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] S. Halabi,et al. Oncology clinical trials : successful design, conduct, and analysis , 2010 .
[12] R. John Davenport,et al. Go or No-Go? , 2003 .
[13] Mark J. Ratain,et al. Measuring response in a post-RECIST world: from black and white to shades of grey , 2006, Nature Reviews Cancer.
[14] Seiichiro Yamamoto,et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. , 2005, The New England journal of medicine.
[15] Haesun Choi,et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] R. Gelman,et al. Dose-response in the treatment of breast cancer: a critical review. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] C. Daugherty. Ethical Issues in the Development of New Agents , 2004, Investigational New Drugs.
[18] S. Prasad,et al. Tumor Response Evaluation in Oncology: Current Update , 2010, Journal of computer assisted tomography.
[19] M. Shapiro,et al. Reporting results from chemotherapy trials. Does response make a difference in patient survival? , 1984, JAMA.
[20] C. Blandizzi,et al. Healthy volunteers and early phases of clinical experimentation , 2010, European Journal of Clinical Pharmacology.
[21] Mark Yoffe,et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. , 2011, The New England journal of medicine.
[22] A. Harris,et al. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? , 1999, Journal of the National Cancer Institute.
[23] T M Therneau,et al. Diagnostic plots to reveal functional form for covariates in multiplicative intensity models. , 1995, Biometrics.
[24] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[25] J. Llinares. A regulatory overview about rare diseases. , 2010, Advances in experimental medicine and biology.
[26] Rupert G. Miller,et al. Survival Analysis , 2022, The SAGE Encyclopedia of Research Design.
[27] Raoul Tibes,et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. , 2009, The New England journal of medicine.
[28] Haesun Choi,et al. We should desist using RECIST, at least in GIST. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] James R. Anderson,et al. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] R. Pazdur. Response rates, survival, and chemotherapy trials. , 2000, Journal of the National Cancer Institute.
[31] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[32] T. Fojo,et al. Progression-Free Survival Is Simply a Measure of a Drug’s Effect While Administered and Is Not a Surrogate for Overall Survival , 2009, Cancer journal.
[33] Thomas J Lynch,et al. The phase III trial in the era of targeted therapy: unraveling the "go or no go" decision. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] Geert Molenberghs,et al. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis , 2000, The Lancet.